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Background: Hip fracture trials often suffer substantial loss to
follow-up due to difficulties locating and communicating with
participants or when participants, or their family members, withdraw
their consent. We aimed to determine which factors were associated
with being unable to contact FAITH and HEALTH participants for
their 24-month follow-up and to also determine which factors were
associated with their withdrawal of consent.
Methods: We conducted 2 multivariable logistic regression
analyses to determine which factors were predictive of being unable
to contact participants at 24 months postfracture and withdrawal of
consent within 24 months of their fracture. Results were reported as
odds ratios, 95% confidence intervals, and associated P-values. All
tests were 2-tailed with alpha = 0.05.
Results: We were unable to contact 123 of 2520 participants (4.9%)
for their 24-month follow-up visits and 124 (4.9%) withdrew their
consent from the trial. Being non-White (P = 0.003), enrolled from a
non-European hospital (P , 0.001), and treated with arthroplasty (P
, 0.001) were associated with an increased odds of not completing
the 24-month follow-up visit. Being enrolled from a hospital in the
United States (P = 0.02), from a hospital in Oceania, India, or South
Africa (P , 0.001) as compared to a European hospital, and treated
with arthroplasty (P , 0.001) were associated with an increased
odds of consent withdrawal.
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Discussion: Certain factors may be predictive of loss to follow-up
in hip fracture trials. We suggest that the identification of such
factors may be used to inform and improve retention strategies in
future orthopaedic hip fracture trials.
Key Words: loss to follow-up, withdrawal of consent, hip fractures
Level of Evidence: Prognostic Level II. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2020;34:S22–S28)
INTRODUCTION
A difficulty frequently faced in hip fracture trials is
loss to follow-up (LTFU), which includes participants not
returning for their follow-up appointments or being
unable to reach participants by telephone for data collec-
tion, as well as participants, or their family members,
withdrawing their consent to participate in the trial.1–3
Even the most rigorously designed orthopaedic hip frac-
ture randomized controlled trials (RCTs) incur the prob-
lem of participant noncompliance with follow-up.1–4 High
LTFU rates may lower the statistical power of a study’s
sample size and can substantially bias the study’s results
if the outcomes of participants remaining in the study
differ from those who were LTFU.3,5 Moreover, high
LTFU may result in a study’s findings no longer reflecting
the sample of patients who were recruited. Therefore, the
minimization of LTFU is an important methodological
consideration.4
The LTFU rates within trials can be quite high, with
previous orthopaedic trauma RCTs reporting up to 28%
LTFU.1 Although hip fracture trials in older adults seem to
have lower rates of LTFU, ranging typically from 2% to
12%,6–8 including the FAITH (6.9%) and HEALTH
(12.0%) trials,9,10 it has been reported that approximately
20% of orthopaedic RCTs fail to report their LTFU.3
Therefore, these rates may actually be higher and remain
an important source of potential bias.3 In other areas of
orthopaedics, LTFU rates exceed the commonly accepted
20% LTFU threshold.11,12 Recent research suggests that
this 20% threshold may not be strict enough to mitigate
the risk of bias incurred due to LTFU in orthopaedic
trials.13 Zelle et al13 made this suggestion based on their
findings that numerous statistically significant orthopaedic
trials’ results became nonsignificant when simulated with
an LTFU rate of 20%. Therefore, Zelle et al13 instead rec-
ommend that researchers aim for a follow-up rate that
exceeds 80%.
Although the HEALTH and FAITH trials both
achieved greater than 80% follow-up, the trial data can
offer insights for both clinicians and researchers on
participant characteristics that may be associated with
being unable to contact participants. The objective of this
preplanned analysis was to investigate and identify which
baseline characteristics were predictive of being unable to
contact participants within 24 months of femoral neck
fracture in patients aged 50 years or older participating in
the HEALTH and FAITH trials.9,10 Although both of these
large, international studies were rigorously designed and
implemented extensive retention strategies, not all partici-
pants were compliant with follow-up. Using the data from
these trials to identify factors that may be predictive of
being unable to contact participants may allow future
researchers to develop more targeted strategies that miti-
gate the risk of LTFU and ensure that the patients retained
represent the sample that was recruited.
METHODS
Definition of Loss to Follow-up in HEALTH
and FAITH Trials
Participants in the HEALTH and FAITH trials were
deemed LTFU after their failure to complete the trial 24-
month visit due to difficulties locating participants or with
participants, or their family members, withdrawing their
consent. Exhaustive measures had been taken by the trial
personnel to contact patients before marking them as lost to
follow-up. These measures included contacting the patient,
their primary care physician, as well as 3 alternative
contacts. Strategies used in the trials to minimize LTFU
included aligning the follow-up schedule with that of their
normal surgical fracture clinic visits, numerous attempts to
contact participants or individuals affiliated with partici-
pants, routine verification of contact, and the selection of
outcomes for which data could be collected through
telephone rather than an in-person visit.
Statistical Methods
Demographics
We examined the demographic and injury characteris-
tics of participants who study personnel were unable to
contact at 24 months, those who withdrew their consent from
the trials, and those who completed their 24-month follow-up
visit. Mean values and SDs were presented for continuous
variables, whereas frequencies and percentages were pre-
sented for categorical variables.
Analyses
We conducted 2 multivariable logistic regression
analyses to investigate the association between selected
factors and not completing the 24-month follow-up and
withdrawing consent, respectively. In the first analysis, the
dependent variable was not completing their 24-month
follow-up visit for the reason that they could not be
contacted in the HEALTH and FAITH studies during the
24-month follow-up period. It should be noted that
participants who died during the 24-month follow-up
period were not included as being LTFU. The number of
independent variables and corresponding levels included in
the 2 analyses were based on the recommendations of
Peduzzi et al.14 Notably, a low number of events per vari-
able (EPV) (ie, EPV values less than 10) can lead to major
problems involving model bias, precision, and significance.
In this analysis, the number of events was the number of
patients who were lost to follow-up, which was 123. To
avoid overfitting and ensure that our EPV was greater than
10, we included 10 variables, with a total of 12 levels. The
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selection of these independent variables was based on pre-
vious literature and expert opinions. The factors included
age, sex, ethnicity [White vs. other (Indigenous, South
Asian, East Asian, Black, or Hispanic/Latino)], body mass
index (underweight [body mass index ,18.5] versus other
(body mass index $18.5), prefracture living setting (insti-
tutionalized vs. not institutionalized), prefracture func-
tional status (use of an aid vs. independent ambulation),
American Society for Anesthesiologists (ASA) physical
status (Class I/II vs. Class III/IV/V), hospital location
[Canada vs. the United States vs. Europe vs. Other
(Oceania, India, and South Africa)], comorbidities (present
vs. not present), and type of surgical treatment (arthro-
plasty vs. internal fixation). We also conducted a multivari-
able logistic regression analysis to investigate the
association between the same selected factors and with-
drawal of consent. The dependent variable was withdrawal
of consent in the HEALTH and FAITH studies during the
24-month follow-up period. The statistical output of these
analyses was reported as odds ratios (ORs) with corre-
sponding 95% confidence intervals (CIs) and associated
P-values. All analyses were conducted using R software




There were 247 of 2520 (9.8%) participants in
HEALTH and FAITH who were LTFU. Specifically, 123
of 2520 (4.9%) participants from the HEALTH (77/1441
participants, 5.3%) and FAITH (46/1079 participants, 4.3%)
trials did not complete their 24-month visit. In addition, 124
of 2520 (4.9%) participants withdrew their consent to
participate in the HEALTH (96/1441, 6.7%) and FAITH
(28/1079 participants, 2.6%) trials.
Table 1 presents the demographic and injury charac-
teristics of participants who did not complete their
24-month follow-up visit, withdrew consent, and those
who were not LTFU. For those 123 participants who did
not complete the 24-month visit (excluding those who
withdrew consent), the mean age was 74.1 (SD 12.0), most
were female (57.7%), White (75.2%), enrolled from a hos-
pital in North America (39.0%), and were not living in an
institutionalized setting prefracture (95.1%). For those 124
participants who withdrew their consent from the trial, the
mean age was 78.4 (SD 9.8), most were female (71.0%),
White (92.7%), enrolled from a hospital in North America
(40.3%), and were not living in an institutionalized setting
prefracture (91.9%). Among those 2397 participants who
were not lost to follow-up, the mean age was 75.9 years
(SD 10.7), most were female (66.4%), White (90.4%),
enrolled from a hospital in Europe (43.7%), and were not
living in an institutionalized setting prefracture (95.0%). It
should be noted that in general, the majority of participants
enrolled in both the FAITH and HEALTH trials were
White (82.4% and 95.1%, respectively).
Factors Associated with LTFU
Participants of Indigenous, South Asian, East Asian,
Black, or Hispanic/Latino ethnicity (OR vs. White 2.17, 95%
CI: 1.30–3.61; P = 0.003) were at an increased odds of not
completing the 24 month follow-up in the FAITH and
HEALTH trials. Participants who were enrolled from a hos-
pital in Canada (OR vs. Europe 2.51, 95% CI: 1.42–4.44; P,
0.001), from a hospital in the United States (OR vs. Europe
4.72, 95% CI: 2.73–8.17; P , 0.001), from a hospital in
Oceania, India, or South Africa (OR vs. Europe 3.91, 95%
CI: 1.96–7.82; P , 0.001), and treated with arthroplasty (OR
vs. internal fixation 2.67, 95% CI: 1.71–4.17; P , 0.001)
were also at an increased odds. Age, sex, body mass index,
prefracture living setting, prefracture functional status, ASA
physical status, and presence of a comorbidity were not found
to be associated with not completing the 24-month visit
(Table 2).
Similar to the first analysis, participants who were
enrolled from a hospital in the United States (OR vs. Europe
1.77, 95% CI: 1.10–2.86; P = 0.02), from a hospital in
Oceania, India, or South Africa (OR vs. Europe 2.75, 95%
CI: 1.53–4.95; P , 0.001), and treated with arthroplasty (OR
vs. internal fixation 3.10, 95% CI: 1.92–5.01; P , 0.001)
were at an increased odds of withdrawing consent in the
FAITH and HEALTH trials. In contrast to the prior analysis,
we found that not having a comorbidity approached statistical
significance (OR 1.79, 95% CI 0.99–3.23; P = 0.053) for
being associated with an increased odds of withdrawing con-
sent. Age, ethnicity, body mass index, prefracture living set-
ting, prefracture functional status, and ASA physical status
were also not found to be associated with withdrawing con-
sent (Table 2).
DISCUSSION
The results of this analysis show that certain participant
characteristics and clinical variables, including ethnicity,
country of the participating hospital, and type of surgical
treatment, have an impact on LTFU in femoral neck fracture
patients aged 50 years or older. Specifically, participants with
an ethnicity other than White, enrolled from a hospital not
located in Europe, and treated with arthroplasty were at an
increased odds of being lost to follow-up. Surprisingly, other
factors, including sex, age, body mass index, prefracture
living setting, prefracture functional status, and ASA class,
were found to not be associated with LTFU in this population.
Our results as well as other orthopaedic studies on predicting
factors of LTFU have highlighted significant health care
disparities that need to be addressed in terms of ethnicity,
disability, unemployment, and social support, to name a
few.1,15–18 Identifying predictors of LTFU will help future
trials in targeting their “retention efforts” in the participants
associated with higher risk of LTFU.
Previous literature supports our finding that the country
of the participating hospital is associated with LTFU. A
systematic review investigating LTFU rates in 559 orthopae-
dic studies of 131,836 participants identified that treatment in
the United States as compared to other countries was a
predictive factor of LTFU (P = 0.01).3 Somerson et al3
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indicated that the reasons for this difference remain unclear
and are likely multifactorial. Similarly, in an RCT of 2381
adults with an open fracture, participants who received treat-
ment in the United States (which has a predominantly
privately funded health care system) were more likely to be
LTFU than those who received treatment in Canada, Europe,
or Australia (which have publicly funded health care systems)
(OR 3.56, 95% CI 2.46–5.17; P , 0.001).4 Although we also
TABLE 1. Patient Demographics
Variable Not LTFU*, N = 2273
Did Not Complete the 24-Month
Visit, N = 123 Withdrew Consent, N = 124
Age, mean (SD) (y) 75.7 (10.7) 74.1 (12.0) 78.4 (9.8)
Sex, n (%)
Male 770 (33.9) 52 (42.3) 36 (29.0)
Female 1503 (66.1) 71 (57.7) 88 (71.0)
Ethnic origin, n (%)
Indigenous 5 (0.2) 2 (1.6) 0 (0.0)
South Asian 125 (5.5) 12 (9.8) 2 (1.6)
East Asian 20 (0.9) 4 (3.3) 1 (0.8)
Black 57 (2.5) 9 (7.3) 5 (4.0)
Hispanic or Latino 14 (0.6) 3 (2.4) 0 (0.0)
White 2041 (89.8) 91 (74.0) 115 (92.7)
Current drugs, n (%)†
None 532 (23.4) 34 (27.6) 24 (19.4)
NSAIDs 299 (13.2) 20 (16.3) 12 (9.7)
General cardiac 824 (36.3) 39 (31.7) 45 (36.3)
Opioid analgesics 188 (8.3) 15 (12.2) 14 (11.3)
Pulmonary drugs 271 (11.9) 12 (9.8) 12 (9.7)
Antihypertension drugs 1189 (52.3) 56 (45.5) 60 (48.4)
Osteoporosis drugs 253 (11.1) 10 (8.1) 14 (11.3)
BMI, n (%) N = 2232 N = 112 N = 115
Underweight (,18.5) 123 (5.4) 10 (8.1) 10 (8.1)
Normal Weight (18.5–24.9) 1152 (50.7) 62 (50.4) 50 (40.3)
Overweight (25.0–29.9) 701 (30.8) 33 (26.8) 37 (29.8)
Obese (.30.0) 256 (11.3) 7 (5.7) 18 (14.5)
Prefracture living setting, n (%)
Institutionalized 110 (4.8) 6 (4.9) 10 (8.1)
Not institutionalized 2163 (95.2) 117 (95.1) 114 (91.9)
Prefracture functional status, n (%)
Use of aid 539 (23.7) 28 (22.8) 33 (26.6)
Independent ambulator 1734 (76.3) 95 (77.2) 91 (73.4)
ASA physical status, n (%)
Class I/II 1213 (53.4) 67 (54.5) 56 (45.2)
Class III/IV/V 1060 (46.6) 56 (45.5) 68 (54.8)
Centre, n (%)
Canada 518 (22.8) 28 (22.8) 15 (12.1)
United States 546 (24.0) 48 (39.0) 35 (28.2)
Europe 994 (43.7) 23 (18.7) 54 (43.5)
Oceania 101 (4.4) 8 (6.5) 19 (15.3)
Africa 5 (0.2) 1 (0.8) 0 (0.0)
India 109 (4.8) 15 (12.2) 1 (0.8)
Comorbidity, n (%)
Yes 2007 (88.3) 102 (82.9) 107 (86.3)
No 266 (11.7) 21 (17.1) 17 (13.7)
Surgical treatment, n (%)
Arthroplasty 1268 (55.8) 77 (62.6) 96 (77.4)
Internal fixation 1005 (44.2) 46 (37.4) 28 (22.6)
*Participants who died during the 24-month follow-up period were captured under the “Not LTFU” group.
†More than one drug could be selected.
ASA, American Society of Anesthesiologists; BMI, body mass index; LTFU, lost to follow-up; SD, standard deviation.
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identified that participants enrolled in hospitals located in
Canada and other counties (Oceania, India, and South
Africa) were at a higher risk of LTFU as compared to those
enrolled in Europe, we are unaware of any studies that have
made comparisons between these locations. Similar to our
primary analysis, our secondary analysis demonstrated that
participants enrolled in hospitals located in the United
States and other countries (Oceania, India, and South
Africa) were at an increased odds of withdrawing consent
as compared to those enrolled in Europe, but to the best of
our knowledge, there have not been previously conducted
studies evaluating predictors of consent withdrawal in ortho-
paedics. Our results suggest that there may be geographic
differences that may have enhanced follow-up and compli-
ance. In Norway and several other European countries, where
nearly all hospitals are government-run, patients “belong” to a
hospital, which is determined by their proximity to the hos-
pital. This European model of “belonging” to a certain hos-
pital may prove to be more successful in participant retention
because for most health issues, patients will have to go to that
particular hospital. In addition, these patients may also feel
more responsible toward their assigned hospital because they
know there is a long-term relationship. To expand on this
further, there have been some studies that have found
decreased participant retention with increased living distance
from their hospital.16,19,20
Similar to our findings, a cohort study of 3202
patients undergoing anterior cruciate ligament reconstruc-
tion found that those of non-White ethnicity (black: OR
3.64; other non-White: OR 1.81) were at a high risk for
2-year LTFU.15 Ramkumar et al15 suggested that the most
pragmatic denominator among the described patients at risk
for LTFU was possibly socioeconomic status, but they were
unable to directly address it in their study other than con-
trolling for level of education and marital status in their
analyses, which still showed an increased LTFU associated
with non-White ethnicities. Other orthopaedic studies have
shown that when controlling for factors, including age, sex,
insurance, income, and education, those of non-White
ethnicity were less likely to receive operative fixation for a
clavicle fracture,21 and benefits from total knee arthroplasty
or total hip arthroplasty.22 In addition, other studies have
suggested better compliance with follow-up when patients
and their physician share the same ethnic identity.23,24
Similar to Ramkumar et al, we were unable to address
socioeconomic status in our analyses. At this time, there is
limited research on what factors contribute to multicultural
participants’ recruitment and retention in studies. It is
highly complex, and as the studies above suggested, there
are other reasons why those of non-White ethnicity access
health care differently and this probably has an impact on
follow-up visit compliance. Collection of information on
TABLE 2. Prognostic Variables Associated With LTFU (n = 2520)
Variable
Did Not Complete the
24-Month Visit (123 Events)
Withdrawal of Consent
(124 Events)
OR (95% CI) P OR (95% CI) P
Ethnicity
Other vs. White 2.17 (1.30–3.61) 0.003 1.79 (0.83–3.89) 0.14
Hospital location Overall: ,0.001 Overall: ,0.001
Canada vs. Europe 2.51 (1.42–4.44) ,0.001 0.58 (0.32–1.05) 0.07
United States vs. Europe 4.72 (2.73–8.17) ,0.001 1.77 (1.10–2.86) 0.02
Other vs. Europe 3.91 (1.96–7.82) ,0.001 2.75 (1.53–4.95) ,0.001
Surgical treatment
arthroplasty vs. internal fixation 2.67 (1.71–4.17) ,0.001 3.10 (1.92–5.01) ,0.001
Age (10-y increase) 0.93 (0.77–1.13) 0.51 1.14 (0.92–1.41) 0.22
Sex
Male vs. female 1.34 (0.91–1.98) 0.20 0.85 (0.56–1.28) 0.45
BMI
Underweight (BMI ,18.5) vs.
other (BMI $18.5)




0.87 (0.36–2.07) 0.63 1.71 (0.85–3.45) 0.13
Prefracture functional status
Use of aid vs. independent
ambulator
1.08 (0.67–1.75) 0.57 1.00 (0.64–1.57) 0.99
ASA physical status
Class III/IV/V vs. Class I/II 0.77 (0.50–1.18) 0.40 1.12 (0.74–1.69) 0.59
Comorbidity
No vs. Yes 1.27 (0.71–2.22) 0.78 1.79 (0.99–3.23) 0.053
ASA, American Society of Anesthesiologists; BMI, body mass index; LTFU, loss to follow-up; OR, odds ratio.
Sivaratnam et al J Orthop Trauma  Volume 34, Number 11 Supplement, November 2020
S26 | www.jorthotrauma.com Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
level of education, working status, marital status, social
support, and income would allow for researchers to assess
the effect of socioeconomic status independently. An
improved understanding of these factors would help ensure
that patients recruited and retained in studies would be
representative of the diverse populations that they are
drawn from. Ensuring diversity would also assist in making
study findings more generalizable to the whole population.
Our findings indicated that participants whose femoral
neck fracture was treated with arthroplasty (OR vs. internal
fixation 2.67, 95% CI: 1.71–4.17; P, 0.001) were associated
with an increased odds of LTFU, as well as an increased odds
of withdrawal of consent (OR vs. internal fixation 3.10, 95%
CI: 1.92–5.01; P , 0.001) within 24 months of femoral neck
fracture. To the best of our knowledge, no other orthopaedic
trauma studies have evaluated the impact of surgical treat-
ment for femoral neck fracture patients on LTFU, nor on
withdrawal of consent. However, a systematic review and
meta-analysis of 8 RCTs comparing arthroplasty to internal
fixation in 2206 elderly patients with a displaced intracapsular
femoral neck fracture found that those in the arthroplasty
group reported significantly lower complications (risk ratio:
0.56, 95% CI: 0.38–0.80; P , 0.01), reoperations (risk ratio:
0.17, 95% CI: 0.13–0.22; P , 0.00001), revision rates (risk
ratio: 0.11, 95% CI: 0.08–0.16; P , 0.00001), and better
function compared to those treated with internal fixation,
and they were less likely to suffer postoperative pain.25
These findings lead us to suggest that those experiencing
more complications postsurgery may be more likely to return
to clinic for a follow-up visit and, therefore, not be lost to
follow-up. In addition, the increased odds of LTFU in arthro-
plasty patients may be related to arthroplasty being a more
definitive treatment, whereas internal fixation patients require
monitoring to ensure fracture healing, which takes time and
may translate to a greater attendance at follow-up visits.
Another study investigating hip fractures among elderly
patients found that LTFU was highest among patients living
in institutionalized settings, such as nursing homes, as well as
patients who were not independent ambulators, which
differed from our findings of no statistically significant
differences between these groups of patients.26
It should also be noted that there is conflicting evidence
regarding the association of certain factors with LTFU.1,15,27,28
Although not focusing on the elderly hip fracture population,
for example, previous orthopaedic trauma studies of younger
adults investigating LTFU found that male sex is predictive of
LTFU.1,15 These findings were supported by other literature
indicating that women are more inclined to visit their doctors
than men, which in turn might imply that they would be more
likely to attend follow-up appointments.27 By contrast, a study
investigating hip fractures among elderly people found that sex
was not associated with LTFU.28 Age may not be an important
factor in predicting LTFU in the elderly population for the
reason that older participants are less transient and may be
easier to be contacted by study personnel, but other studies
have demonstrated that younger adults may be at a higher risk
of LTFU compared to older adults.4,29 Specifically, in an RCT
of 2381 adults with an open fracture, an age of,30 years (OR
2.16, 95% CI: 1.19–3.95; P = 0.012) significantly increased the
odds of a patient being LTFU.4 Another study found that each
additional year in age reduced the odds of a participant chang-
ing some of their contact information by 2.2% (OR 0.98, 95%
CI: 0.97–0.99), which would allow for study personnel to more
easily contact study participants who are older.
Overall, the literature investigating LTFU in orthopae-
dic trials remains scarce and has not reached consensus on
which factors are predictive of LTFU. Previous literature has
also identified strategies that may be implemented to prevent
LTFU in orthopaedic settings.4 For example, a Cochrane
review suggested that “incentives, communication strategies,
new questionnaire strategies, behavioural or motivational
strategies, case management, and methodological strategies”
could be used to improve retention rates.30 Some of these
strategies were implemented in the FAITH and HEALTH
studies. For example, telephone follow-ups were conducted
when in-clinic visits were not possible.5,13 However, these
strategies may have been more effective if they were focused
on participants who were at higher risk of being lost to
follow-up. We hypothesized that the results of the present
analysis would allow research personnel to be more cognizant
of which participants are more likely to be lost to follow-up,
allowing for targeted implementation of retention strategies.
However, given our findings, a future area of study may entail
evaluating these targeted strategies to help increase retention.
This analysis has both strengths and limitations. The
strengths of this analysis include the use of data from 2 RCTs
that were rigorously designed by the same principal investi-
gators, followed similar follow-up regimens, and had large
sample sizes. In addition, these RCTs enrolled patients from
numerous countries, and thus both of these studies had high
external validity. To the best of our knowledge, determining
predictors of withdrawal of consent has not previously been
evaluated in the field of orthopaedics and therefore, adds
novel findings to the literature. Some of the limitations of the
present analysis are as follows. Given that our data were
retrospectively obtained from 2 completed RCTs, we were
only able to include previously collected variables in the
model. Socioeconomic factors such as alcohol consumption,
smoking habits, and insurance status may have been impor-
tant predictors of LTFU, but such data were not collected in
the HEALTH and FAITH studies and, therefore, we were
unable to analyze these factors. Because the FAITH and
HEALTH trials included older patients, most individuals
were already retired and for that reason, we were unable to
include employment status before injury as a factor in the
model. This factor may have been predictive of LTFU in a
younger population, as has been suggested in previous
literature.1,18,31 Moreover, given that 123 patients were lost
to follow-up, we were limited in the number of factors and
corresponding levels that could be included in our model.
Overall, we conclude that certain characteristics and
clinical variables may be predictive of LTFU in orthopaedic
trials; however, further research must be done. In our study
of elderly hip fracture patients with a 9.8% LTFU rate,
participants with an ethnicity other than White, enrolled
from a hospital not located in Europe, and treated with
arthroplasty were at an increased odds of being lost to
follow-up. Predicting factors for LTFU have previously
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been mainly described for the trauma population so it is
highly likely that the elderly hip fracture population does not
share the same predictors. Additional research is necessary,
given that current literature on this frequently encountered
problem remains scarce, especially in the older hip fracture
population. We suggest that the identification of such factors
may be used to inform and improve retention strategies in
future orthopaedic hip fracture trials.
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